Rubius Therapeutics reports $196.5M loss in 2021

PROVIDENCE – Rubius Therapeutics Inc. on Friday reported a loss of $196.5 million in 2021, or $2.23 per diluted share.  The clinical-stage biopharmaceutical company, which has built a manufacturing facility in Smithfield, reported a $167.7 million loss in 2021, or $2.08 per diluted share. The company is genetically engineering red blood cells to create an…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

If you have already logged in and are still seeing this message, please refresh the page as your browser is caching the old content.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.